08/10/23 7:30 AMNasdaq : SESN, CARM earningsCarisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsCarisma Therapeutics Inc., a clinical-stage biopharmaceutical...RHEA-AIneutral
03/02/23 11:32 AMNasdaq : SESN acquisitionSesen Bio Stockholders Approve Merger with Carisma TherapeuticsSesen Bio, Inc., today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc., at the Company’ s Special Meeting of Stockholders held earlier today. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said,“ We are pleased with the outcome of today’ s Special Meeting and thank...RHEA-AIpositive
02/28/23 8:00 AMNasdaq : SESN earningsSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsOn February 13, 2023, following extensive engagement with Sesen Bio stockholders, Sesen Bio and Carisma Therapeutics, Inc. further amended the previously amended merger agreement announced on December 29, 2022. On February 16, 2023 and February 17, 2023, leading independent proxy advisors Institutional Shareholder Services and Glass, Lewis& Co.,...RHEA-AIneutral
02/21/23 9:00 AMNasdaq : SESN acquisitionLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With CarismaSesen Bio, Inc., today announced that leading independent proxy advisory firm Glass, Lewis& Co. recommends that stockholders vote“ FOR” all proposals, including the pending merger with Carisma Therapeutics Inc., in advance of the Company’ s upcoming Special Meeting of Stockholders scheduled for March 2, 2023. "...we believe it is reasonable to conclude that the...RHEA-AIpositive
02/16/23 4:42 PMNasdaq : SESN Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingSesen Bio, Inc., today announced that Institutional Shareholder Services recommends that stockholders vote“ FOR” all proposals, including the pending merger with Carisma Therapeutics Inc., at the Company’ s upcoming Special Meeting of Stockholders scheduled for March 2, 2023. “appears to have conducted a thorough overview of alternatives and is proposing to...RHEA-AIpositive
02/16/23 8:00 AMNasdaq : SESN conferencesacquisitionSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerSesen Bio, Inc. today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. management team on Tuesday, February 21, 2023, at 8:00 am ET. Sesen Bio stockholders can submit questions in advance to ir@sesenbio.com. The webcast, which can be accessed on the Events and Presentations link on the Sesen...RHEA-AIneutral
02/15/23 8:00 AMNasdaq : SESN acquisitionBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsSesen Bio, Inc., today announced that BML Investment Partners, L.P., one of Sesen Bio’ s top stockholders, intends to vote all of its shares in support of the Company’ s pending merger with Carisma Therapeutics Inc.. With a substantial special cash dividend, enhanced CVR and exciting long-term potential of Carisma, we believe this represents the best path forward for...RHEA-AIpositive
02/14/23 8:00 AMNasdaq : SESN dividendsacquisitionSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerSesen Bio, Inc. and Carisma Therapeutics Inc., a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the companies have reached a voting and support agreement with Bradley L. Radoff and Michael Torok. In connection with the Support...RHEA-AIpositive
02/02/23 4:30 PMNasdaq : SESN acquisitionSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics MergerSesen Bio, Inc. today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc.. The merger with Carisma delivers substantial and immediate value for Sesen Bio stockholders, which is meaningfully better than the alternative of dissolution and liquidation Expected special one-time cash dividend of...RHEA-AIneutral
01/30/23 8:00 AMNasdaq : SESN Sesen Bio Receives NASDAQ Delisting NoticeSesen Bio, Inc. today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC that, based upon the Company’ s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company’ s common stock is subject to delisting. The receipt of this notice from Nasdaq...RHEA-AIneutral